Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental issues like puberty that are not present in adult disease.

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca (NASDAQ:AZN) announced Thursday that gefurulimab, its experimental injectable for generalized myasthenia gravis, ...

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and older with generalized myasthenia gravis who are anti-acetylcholine ...

In an announcement by the National Institute for Health and Care Excellence (NICE) it confirms that Zilucoplan (Zilbrysq) ...

Nipocalimab (Imaavy; Johnson & Johnson) was approved by the FDA on April 30, 2025, to treat generalized myasthenia gravis in adult patients and pediatric patients 12 years or older who are anti ...

Results of a recent database analysis reveal that patients with juvenile myasthenia gravis—particularly prepubescent girls—might benefit from early thymectomy to cut production of autoreactive ...

The landscape of gMG treatment is rapidly evolving, said John Morren, MD, of the Cleveland Clinic. The traditional approach to managing gMG involves broad immunosuppressive therapies, but emerging ...

I sold my house, packed up my kids, ... Andrea Divis, 52, was diagnosed with generalized myasthenia gravis in 2019. Within two weeks of the start of symptoms, she received her diagnosis.

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially ...

Ocular myasthenia gravis affects the muscles that control the eyes and eyelids. Learn about the symptoms, causes, treatments, and more.